Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial128

File Visits

Downloads
VERSION EDITOR.pdf28

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial45

Number of downloads in the range

Downloads
VERSION EDITOR.pdf13

Views

Views
October 20251
November 20255
December 20257
January 202614
February 20261
March 20266
April 202611
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • October 2025
    0
  • November 2025
    0
  • December 2025
    4
  • January 2026
    3
  • February 2026
    1
  • March 2026
    3
  • April 2026
    2
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
United States29
United Kingdom2
Argentina1
Australia1
Bolivia1
Brazil1
Canada1
China1
Costa Rica1
Ecuador1
 

Top countries by downloads

Downloads
United States11
United Kingdom1
 

Top cities views

Views
San Jose11
Ashburn7
Anselmo Llorente1
Brooklyn1
Chino Valley1
Cochabamba1
Jersey City1
Johannesburg1
Lima1
Los Angeles1
 

Top cities by downloads

Downloads
Ashburn1